Novel nanoemulsion for minimizing variations in bioavailability of ezetimibe

References

• Ahmed M, Ramadan W, Rambhu D, Shakeel F. (2008). Potential of nanoemulsions for intravenous delivery of rifampicin. Pharmazie, 63: 806–811.
   PubMed Web of Science ®Google Scholar
• Ambike AA, Mahadik KR, Paradkar A. (2005). Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations. Pharm Res, 22: 990–998.
   PubMed Web of Science ®Google Scholar
• Attwood D, Mallon C, Taylor CJ. (1992). Phase studies on oil-in-water phospholipid microemulsions. Int J Pharm, 84: R5–R8.
   Web of Science ®Google Scholar
• Basha SJ, Naveed SA, Tiwari NK, Shashikumar D, Muzeeb S, Kumar TR, Kumar NV, Rao NP, Srinivas N, Mullangi R, Srinivas NR. (2007). Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection: quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bile. J Chromatogr B Analyt Technol Biomed Life Sci, 853: 88–96.
   PubMed Web of Science ®Google Scholar
• Bolkent S, Yanardag R, Karabulut-Bulan O, Yesilyaprak B. (2005). Protective role of Melissa officinalis L. extract on liver of hyperlipidemic rats: a morphological and biochemical study. J Ethnopharmacol, 99: 391–398.
   PubMed Web of Science ®Google Scholar
• Constantinides PP. (1995). Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res, 12: 1561–1572.
   PubMed Web of Science ®Google Scholar
• Dixit RP, Nagarsenker MS. (2008a). Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Eur J Pharm Sci, 35: 183–192.
   PubMed Web of Science ®Google Scholar
• Dixit RP, Nagarsenker MS. (2008b). Formulation and in vivo evaluation of self-nanoemulsifying granules for oral delivery of a combination of ezetimibe and simvastatin. Drug Dev Ind Pharm, 34: 1285–1296.
   PubMed Web of Science ®Google Scholar
• Doshi AS, Kachhadia PK, Joshi HS. (2008). Validation of a stability-indicating LC method for assay of ezetimibe in tablets and for determination of content uniformity. Chromatographia, 67: 137–142.
   Web of Science ®Google Scholar
• Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK. (2001). A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther, 23: 871–885.
   PubMed Web of Science ®Google Scholar
• Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep, 50: 219–244.
   PubMedGoogle Scholar
• Ghosh MN, ed. (2005). Fundamentals of Experimental Pharmacology (p. 192). Chapter 30. Toxicity studies. Kolkata: Hilton and Company Publishers.
   Google Scholar
• Ghosh PK, Murthy RS. (2006). Microemulsions: a potential drug delivery system. Curr Drug Deliv, 3: 167–180.
   PubMedGoogle Scholar
• Jeu L, Cheng JW. (2003). Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther, 25: 2352–2387.
   PubMed Web of Science ®Google Scholar
• Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, Lee HB, Cho SH. (2004). Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm, 274: 65–73.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet, 44: 467–494.
   PubMed Web of Science ®Google Scholar
• Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45: 89–121.
   PubMed Web of Science ®Google Scholar
• Lipka LJ. (2003). Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovasc Drug Rev, 21: 293–312.
   PubMed Web of Science ®Google Scholar
• Nerurkar MM, Burton PS, Borchardt RT. (1996). The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res, 13: 528–534.
   PubMed Web of Science ®Google Scholar
• Patel R, Bhimani D, Patel J, Patel D. (2008). Solid-state characterization and dissolution properties of ezetimibe–cyclodextrins inclusion complexes. J Incl Phenom Macro, 60: 241–251.
   Web of Science ®Google Scholar
• Patel AR, Vavia PR. (2007). Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J, 9: E344–E352.
   PubMed Web of Science ®Google Scholar
• Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, Cayen MN. (2002). Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos, 30: 430–437.
   PubMed Web of Science ®Google Scholar
• Pouton CW. (1997). Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev, 25: 47–58.
   Web of Science ®Google Scholar
• Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. (2007). Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm, 66: 227–243.
   PubMed Web of Science ®Google Scholar
• Sistla R, Tata VS, Kashyap YV, Chandrasekar D, Diwan PV. (2005). Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms. J Pharm Biomed Anal, 39: 517–522.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Khar RK, eds. (2002). Targeted and Controlled Drug Delivery (p. 280). Chapter 7. Submicronemulsions. New Delhi: CBS Publishers.
   Google Scholar